#1 Clinical Trials Search in Europe

Stx-241

A groundbreaking clinical trial is underway to evaluate STX-241, a novel drug designed to combat advanced non-small cell lung cancer (NSCLC) that has become resistant to existing treatments. This study aims to assess the safety, effectiveness, and optimal dosage of STX-241 in patients whose cancer has progressed despite previous therapies. The trial represents a significant step forward in the quest for more effective treatments for this challenging form of lung cancer.

Table of Contents

What is STX-241?

STX-241 is a new drug being developed to treat Non-Small Cell Lung Cancer (NSCLC). It’s specifically designed for patients whose cancer has become resistant to other treatments called EGFR tyrosine kinase inhibitors (TKIs).[1]

This medication is taken orally as a film-coated tablet, which means you can swallow it like a regular pill. It’s intended for patients with locally advanced or metastatic NSCLC. Locally advanced means the cancer has spread to nearby tissues or lymph nodes, while metastatic means it has spread to other parts of the body.[1]

How Does STX-241 Work?

STX-241 is described as a fourth generation EGFR TKI. Here’s what this means:

  • EGFR: This stands for Epidermal Growth Factor Receptor, a protein on cells that helps them grow and divide. Some NSCLC cells have too much EGFR, causing them to grow out of control.
  • TKI: Tyrosine Kinase Inhibitor, a type of drug that blocks the action of EGFR.
  • Fourth generation: This means it’s a newer, more advanced version of this type of drug, designed to work when earlier versions have stopped being effective.

STX-241 is designed to be mutant selective, meaning it targets specific changes (mutations) in cancer cells. It’s also CNS-penetrant, which means it can reach the Central Nervous System (brain and spinal cord). This is important because lung cancer can sometimes spread to the brain.[1]

Clinical Trial Overview

STX-241 is currently being studied in a clinical trial. This is a First-In-Human (FIH) trial, which means it’s the first time this drug is being tested in people. The trial is described as Phase I/II, combining two stages of testing:[1]

  • Phase I: This stage focuses on finding the right dose and checking for side effects.
  • Phase II: This stage starts to look at how well the drug works against the cancer.

The main goals of this trial are to:

  1. Establish the safety profile of STX-241
  2. Determine the best dose for future studies (called the Recommended Phase II Dose or RP2D)
  3. Explore how the drug moves through and affects the body
  4. Assess how effective the drug is against NSCLC

Trial Structure

The trial is divided into three parts:[1]

  1. Part 1 (Phase Ia): This part focuses on gradually increasing the dose to find the right amount. Patients will receive STX-241 twice daily at different fixed doses (10 mg, 20 mg, 40 mg, 80 mg, 120 mg, 180 mg).
  2. Part 2 (Phase Ib): This part will further refine the dosing, using information from Part 1.
  3. Part 3 (Phase II): This part will test the effectiveness of STX-241 at the dose determined in Parts 1 and 2.

Safety and Effectiveness Measures

The trial will closely monitor patients for side effects and how well the drug works. Some key measures include:[1]

  • Safety: Tracking any side effects (called adverse events) and how severe they are.
  • Tolerability: Checking if patients need to reduce their dose or stop taking the drug due to side effects.
  • Effectiveness: Measuring how many patients’ tumors shrink or stop growing (called response rate and disease control rate).
  • Survival: Looking at how long patients live without their cancer getting worse (progression-free survival) and overall survival.

What to Expect During the Trial

If you participate in this trial, here’s what you might expect:[1]

  • You’ll take STX-241 tablets twice a day, every day.
  • You’ll have regular check-ups and tests to monitor your health and the effects of the drug.
  • Your tumor will be measured regularly using scans to see if the drug is working.
  • You’ll have blood tests to see how your body processes the drug.
  • The trial will last up to 24 months, with additional follow-up after you stop taking the drug.

It’s important to remember that while this drug shows promise, it’s still in the testing phase. The trial aims to determine if STX-241 is safe and effective for treating NSCLC in patients who have developed resistance to other treatments.

Aspect Details
Drug Name STX-241
Drug Type Fourth generation EGFR TKI, CNS-penetrant, mutant selective
Administration Oral, twice daily
Target Condition Locally advanced or metastatic NSCLC resistant to EGFR TKIs
Trial Phase Phase I/II
Primary Objectives Safety profile, RP2D determination, PK/PD properties, efficacy assessment
Key Outcomes Measured Safety, tolerability, MTD, OBD, RP2D, cORR
Secondary Outcomes PK parameters, DCR, TTR, DOR, PFS, Overall Survival

FAQ

  • What is STX-241? STX-241 is a new drug being tested for patients with advanced non-small cell lung cancer (NSCLC) that has become resistant to other treatments. It is a fourth-generation EGFR TKI that can penetrate the central nervous system and is designed to target specific mutations in cancer cells.
  • Who is eligible for this clinical trial? The trial is for patients with locally advanced or metastatic NSCLC that has progressed during or after treatment with third-generation EGFR TKIs like osimertinib, particularly due to C797X double acquired mutations.
  • How is STX-241 administered? STX-241 is given as a film-coated tablet that is taken orally (by mouth) twice daily. The dosage varies depending on the phase of the trial, ranging from 10 mg to 180 mg.
  • What are the main goals of this clinical trial? The primary goals are to establish the safety profile of STX-241, determine the best dose for future studies, understand how the drug behaves in the body, and assess its effectiveness in treating NSCLC.
  • How long does the trial last? The trial duration varies, with some assessments occurring over 24 months. Participants are also monitored for safety for 30 days after their last dose of STX-241.

Ongoing Clinical Trials on Stx-241

  • Study on the Safety and Effects of STX-241 for Patients with Advanced Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany The Netherlands Spain

Glossary

  • NSCLC: Non-Small Cell Lung Cancer, a type of lung cancer that is less aggressive than small cell lung cancer but more common, accounting for about 80-85% of all lung cancers.
  • EGFR TKI: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, a type of targeted therapy used to treat certain types of cancer, including some forms of NSCLC.
  • First-In-Human (FIH): The first time a new drug is tested in human subjects, typically after showing promise in laboratory and animal studies.
  • Pharmacokinetic (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamic (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Recommended Phase II Dose (RP2D): The dose of a drug determined to be safe and potentially effective, which is then used in larger Phase II clinical trials.
  • Central Nervous System (CNS): The part of the nervous system consisting of the brain and spinal cord.
  • C797X mutations: Specific genetic changes in cancer cells that can make them resistant to certain cancer treatments.
  • Dose-Limiting Toxicities (DLTs): Side effects of a drug that are severe enough to prevent increasing the dose or require a dose reduction.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure if tumors are responding to treatment in cancer clinical trials.

References